Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory examination and pathological activation. A platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of treatment programs related to the treatment and treatment of the beta 2 microprotein sample dialysis require individualized development, typically including drug therapy, rehabilitation interventions, regular follow-up, and multidimensional management.
In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of β2 microprotein polymerization dialysis.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.